Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-33901 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- LPAR6 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Percent identity with other species by BLAST analysis: Human, Gorilla, Gibbon (100%) Monkey (94%) Mouse, Rat, Hamster, Rabbit (88%) Bat (81%).
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 50 µg
- Concentration
- 1 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma.
He J, Gao R, Meng M, Yu M, Liu C, Li J, Song Y, Wang H
International journal of environmental research and public health 2021 Oct 20;18(21)
International journal of environmental research and public health 2021 Oct 20;18(21)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of formalin-fixed paraffin-embedded human thymus using a LPAR6/P2Y5 polyclonal antibody (Product # PA5-33901). Heat-induced antigen retrieval was performed prior to staining.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 9 Higher expression of LPAR6 was correlated with clinicopathological parameters in LUAD cohort and was associated with increased overall survival (OS) of LUAD and LUSC patients. ( A ) Immunohistochemistry staining of the LPAR6 in the tumor and adjacent normal tissues. Red arrows indicated the cytoplasm-stained LPAR6. Bar, 50 mum; ( B ) The immunoreactive score (IRS) of the cytoplasm LPAR6 staining in 74 paired lung cancer tissues in LUAD cohort; ( C ) The Kaplan-Meier plot of the OS for lung cancer patients with relatively higher or lower LPAR6 expression levels in LUAD cohort (N = 74; Log-rank test, p = 0.02); ( D ) The IRS of the cytoplasm LPAR6 staining in 78 paired lung cancer tissues in LUSC cohort; ( E ) The Kaplan-Meier plot of the overall survival for lung cancer patients with relatively higher or lower LPAR6 expression levels in LUSC cohort (N = 78; log-rank test, p = 0.04). ( F , G ) The proportion of LPAR6 expression level (higher or lower) in different clinical stages, lymph node metastasis, organ metastasis and tumor size of patients in LUAD ( F ) and LUSC ( G ) cohorts.
